Glaukos Co. (NYSE:GKOS) Shares Bought by California Public Employees Retirement System


Share on StockTwits

California Public Employees Retirement System lifted its holdings in shares of Glaukos Co. (NYSE:GKOS) by 3.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 91,372 shares of the medical instruments supplier’s stock after buying an additional 2,672 shares during the period. California Public Employees Retirement System’s holdings in Glaukos were worth $6,877,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Aperio Group LLC grew its stake in shares of Glaukos by 10.1% in the third quarter. Aperio Group LLC now owns 10,078 shares of the medical instruments supplier’s stock valued at $499,000 after buying an additional 925 shares in the last quarter. OLD National Bancorp IN acquired a new stake in shares of Glaukos during the 3rd quarter valued at approximately $211,000. Exchange Traded Concepts LLC grew its position in shares of Glaukos by 74.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 13,960 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 5,937 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Glaukos in the third quarter worth $25,271,000. Finally, Comerica Bank raised its holdings in shares of Glaukos by 10.5% during the third quarter. Comerica Bank now owns 46,616 shares of the medical instruments supplier’s stock valued at $2,715,000 after buying an additional 4,419 shares during the last quarter.

NYSE GKOS opened at $94.91 on Tuesday. The company has a quick ratio of 9.31, a current ratio of 9.73 and a debt-to-equity ratio of 0.37. Glaukos Co. has a 12-month low of $23.31 and a 12-month high of $97.79. The company has a 50 day moving average price of $87.96 and a two-hundred day moving average price of $60.69. The stock has a market capitalization of $4.27 billion, a PE ratio of -57.52 and a beta of 1.87.

A number of research firms have recently commented on GKOS. Oppenheimer initiated coverage on Glaukos in a research note on Tuesday, December 8th. They issued a “market perform” rating and a $73.00 price objective on the stock. Smith Barney Citigroup raised shares of Glaukos from a “sell” rating to a “neutral” rating and upped their price target for the company from $50.00 to $72.00 in a report on Wednesday, December 16th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upgraded shares of Glaukos from a “sell” rating to a “neutral” rating and raised their price objective for the company from $50.00 to $72.00 in a research report on Wednesday, December 16th. Piper Sandler downgraded shares of Glaukos from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $70.00 to $80.00 in a report on Friday, January 29th. Finally, TheStreet upgraded shares of Glaukos from a “d+” rating to a “c” rating in a report on Monday, November 30th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $58.40.

In other Glaukos news, Director William J. Phd Link sold 50,000 shares of Glaukos stock in a transaction on Tuesday, December 1st. The shares were sold at an average price of $67.97, for a total transaction of $3,398,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joseph E. Gilliam sold 13,750 shares of Glaukos stock in a transaction dated Tuesday, February 9th. The shares were sold at an average price of $96.58, for a total transaction of $1,327,975.00. The disclosure for this sale can be found here. 8.70% of the stock is currently owned by corporate insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Recommended Story: Day Trading – Risk Worth the Reward?

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.